3,330 Shares in Illumina, Inc. (NASDAQ:ILMN) Acquired by GF Fund Management CO. LTD.

GF Fund Management CO. LTD. acquired a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 3,330 shares of the life sciences company's stock, valued at approximately $445,000.

A number of other large investors have also recently made changes to their positions in the business. Sunbelt Securities Inc. raised its position in Illumina by 144.4% in the 4th quarter. Sunbelt Securities Inc. now owns 716 shares of the life sciences company's stock valued at $96,000 after buying an additional 423 shares during the last quarter. GTS Securities LLC grew its stake in shares of Illumina by 7,215.2% in the 4th quarter. GTS Securities LLC now owns 2,348 shares of the life sciences company's stock worth $314,000 after acquiring an additional 2,381 shares in the last quarter. Fourth Dimension Wealth LLC purchased a new stake in shares of Illumina in the fourth quarter valued at about $40,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Illumina by 2.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,292,407 shares of the life sciences company's stock valued at $172,704,000 after purchasing an additional 32,270 shares in the last quarter. Finally, Vident Advisory LLC boosted its holdings in Illumina by 1,269.2% during the fourth quarter. Vident Advisory LLC now owns 99,348 shares of the life sciences company's stock worth $13,276,000 after purchasing an additional 92,092 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ILMN shares. Stephens reiterated an "overweight" rating and issued a $105.00 price objective on shares of Illumina in a research note on Tuesday, May 20th. TD Cowen cut shares of Illumina from a "buy" rating to a "hold" rating and dropped their target price for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Robert W. Baird dropped their target price on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 5th. Royal Bank of Canada decreased their price objective on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a report on Tuesday, April 8th. Finally, Hsbc Global Res downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $128.15.

Illumina Price Performance

Shares of ILMN stock traded up $1.94 during trading hours on Wednesday, reaching $84.43. The stock had a trading volume of 2,409,530 shares, compared to its average volume of 2,329,649. The stock's fifty day simple moving average is $78.00 and its 200 day simple moving average is $107.72. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66. The firm has a market capitalization of $13.37 billion, a PE ratio of -10.99, a PEG ratio of 1.60 and a beta of 1.35.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same period last year, the business earned $0.98 earnings per share. Illumina's revenue was down 1.4% compared to the same quarter last year. On average, equities research analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Insider Activity

In related news, CFO Ankur Dhingra purchased 6,100 shares of the firm's stock in a transaction dated Monday, May 12th. The shares were purchased at an average price of $81.21 per share, with a total value of $495,381.00. Following the acquisition, the chief financial officer now directly owns 24,906 shares of the company's stock, valued at approximately $2,022,616.26. This represents a 32.44% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.60% of the stock is owned by company insiders.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.